Abstract
Radiotherapy has important role in the palliation of metastatic non-small cell lung cancer (NSCLC). Randomized trials tend to suggest that, in general, short regimens give similar palliation though with more long term toxicity compared to longer regimens. Hypofractionated radiotherapy has been the standard of care for the palliative management of lung cancer since decades. Stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) are forms of extreme hypofractionation being used more frequently in the treatment of single or oligometastases. In general, they offer good tumor control with little toxicity (at a more expensive cost) compared to the traditionally fractionated radiotherapy regimens. The combination of targeted therapy with radiotherapy is an evolving concept in the management of metastatic lung cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
